Looking for Sentiment Analysis? Discover the most popular stocks on Reddit by using our Sentiment Tracker
CRMD - CorMedix Inc.
Market Cap 218.91M P/E - EPS this Y 35.20% Ern Qtrly Grth -
Income -53.12M Forward P/E -4.60 EPS next Y 116.90% 50D Avg Chg -9.00%
Sales 806.12k PEG - EPS past 5Y - 200D Avg Chg -2.00%
Dividend N/A Price/Book 3.42 EPS next 5Y - 52W High Chg -48.00%
Recommedations 2.00 Quick Ratio 4.12 Shares Outstanding 55.86M 52W Low Chg 53.00%
Insider Own 0.95% ROA -63.33% Shares Float 55.32M Beta 1.59
Inst Own 30.88% ROE -111.55% Shares Shorted/Prior 10.38M/10.32M Price 4.14
Gross Margin -64.79% Profit Margin - Avg. Volume 748,320 Target Price 12.50
Oper. Margin -1,898.09% Earnings Date Nov 12 Volume 548,683 Change -3.50%
Healthcare | Biotechnology | United States
About CorMedix Inc.

CorMedix Inc., a biopharmaceutical company, focuses on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory diseases in the United States. Its lead product candidate is DefenCath, an antimicrobial catheter lock solution to reduce the incidence of catheter-related bloodstream infections in adult patients with kidney failure. The company was formerly known as Picton Holding Company, Inc. and changed its name to CorMedix, Inc. in January 2007. CorMedix Inc. was incorporated in 2006 and is based in Berkeley Heights, New Jersey.

CorMedix Inc. News
12/20/24 CorMedix price target raised to $12 from $11 at RBC Capital
12/19/24 CorMedix Inc. Added to Nasdaq Biotechnology Index
11/26/24 CorMedix Inc. Supports CMS Policy Updates Regarding Access to Innovative Drug Products
11/04/24 CorMedix Inc. to Participate in the Truist Securities BioPharma Symposium
11/04/24 Rainbows and Unicorns: CorMedix Inc. (NASDAQ:CRMD) Analysts Just Became A Lot More Optimistic
11/01/24 While shareholders of CorMedix (NASDAQ:CRMD) are in the black over 1 year, those who bought a week ago aren't so fortunate
10/31/24 Cormedix Inc (CRMD) Q3 2024 Earnings Call Highlights: Strong Revenue Growth Amid Rising Expenses
10/30/24 CorMedix Inc. Reports Third Quarter and Nine Month 2024 Financial Results and Provides Business Update
10/24/24 CorMedix Inc. Announces New Data at ASN Kidney Week 2024
10/23/24 CorMedix Inc. to Report Third Quarter 2024 Financial Results and Provide a Corporate Update on October 30, 2024
10/08/24 CorMedix Announces New Commercial Agreement with Mid-Sized Dialysis Operator
06:06 AM CorMedix Inc. (NASDAQ:CRMD): When Will It Breakeven?
09/19/24 CorMedix Inc. Announces New Commercial Agreement
09/13/24 CorMedix Inc. to Present at the Cantor Global Healthcare Conference
08/15/24 We Think CorMedix (NASDAQ:CRMD) Can Afford To Drive Business Growth
08/14/24 CorMedix Inc. Reports Second Quarter and Six Month 2024 Financial Results and Provides Business Update
08/07/24 CorMedix Inc. to Report Second Quarter 2024 Financial Results and Provide a Corporate Update on August 14, 2024
07/31/24 These 2 “Strong Buy” Penny Stocks Are Poised for a Big Rally, Say Analysts
07/03/24 CorMedix Inc. Announces Outpatient Availability of DefenCath
06/18/24 CorMedix Inc. Receives FDA Feedback on Potential Label Expansion
Insider Trades Relationship Date Transactions Cost($) #Shares Value($) #Share Own SEC Form 4
Costa Paulo F Director Director May 17 Buy 4.65 10,000 46,500 10,000 05/18/23
Stewart Robert A Director Director May 17 Buy 4.3735 10,000 43,735 11,000 05/18/23
Todisco Joseph Chief Executive Offi.. Chief Executive Officer May 17 Buy 4.58 5,000 22,900 209,726 05/18/23
Todisco Joseph Chief Executive Offi.. Chief Executive Officer Nov 15 Buy 3.82 20,000 76,400 242,169 11/16/22
Todisco Joseph Chief Executive Offi.. Chief Executive Officer Aug 24 Buy 3.9200 4,700 18,424 222,169 08/25/22
Kaplan Myron Director Director May 17 Buy 3.78 5,000 18,900 160,034 05/18/22
Todisco Joseph Chief Executive Offi.. Chief Executive Officer May 16 Buy 3.3800 10,000 33,800 217,469 05/17/22